Location: Diet, Genomics and Immunology Laboratory
Project Number: 8040-51530-058-014-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Mar 1, 2022
End Date: Feb 28, 2025
To understand the role of DHA and EPA on lipid mediators and gut microbiota composition and its impact on organ and mucosal sites through signaling mechanisms and/or bioactive molecules. We will test the hypothesis that EPA and DHA can prevent microbiota dysbiosis by promoting the synthesis of several key specialized pro-resolving lipid mediators (SPMs ) and their ability to modulate selective gut microbiota growth.
Three objectives are proposed: Objective 1. Determine the effects of EPA and DHA, relative to a high-fat control diet, on gut microbiota composition and colon SPM concentrations in LDLR-/- and LDLR-/-/15LOX-/- mice. Objective 2. Compare the effects of EPA and DHA, relative to a high-fat control diet, on serum LPS and gut SCFA concentrations, peritoneal macrophage inflammatory response and aortic atherosclerosis in LDLR-/- versus LDLR-/-/15LOX-/- mice and relate these effects to differences in SPMs. Objective 3. Identify the differential effects of EPA and DHA on gut microbiota, peritoneal macrophage inflammatory cell response and atherosclerosis.